Pieris Pharmaceuticals Inc Share Price OTC Bulletin Board
Equities
PIRS
US7207951036
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- | - |
19/04 | Pieris Pharmaceuticals Shares Fall After 1-for-80 Reverse Stock Split Announcement | MT |
03/04 | North American Morning Briefing : Powell Awaited -2- | DJ |
Sales 2022 | 25.9M 0 2.16B | Sales 2023 | 42.81M 0 3.56B | Capitalization | 17.99M 0 1.5B |
---|---|---|---|---|---|
Net income 2022 | -33M - -2.75B | Net income 2023 | -24M - -2B | EV / Sales 2022 | 1.21 x |
Net cash position 2022 | 46.07M 0 3.84B | Net cash position 2023 | 26.37M 0 2.2B | EV / Sales 2023 | -0.2 x |
P/E ratio 2022 |
-2.32
x | P/E ratio 2023 |
-0.67
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 92.57% |
Latest transcript on Pieris Pharmaceuticals Inc
Managers | Title | Age | Since |
---|---|---|---|
Stephen Yoder
CEO | Chief Executive Officer | 48 | 01/10/01 |
Thomas Bures
DFI | Director of Finance/CFO | 49 | 01/17/01 |
Kayti Aviano
CTO | Chief Tech/Sci/R&D Officer | - | 01/17/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 59 | 20/16/20 | |
James Geraghty
CHM | Chairman | 69 | 22/17/22 |
Michael Richman
BRD | Director/Board Member | 63 | 17/14/17 |
1st Jan change | Capi. | |
---|---|---|
+9.42% | 114B | |
+11.84% | 104B | |
-14.15% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.16% | 17.89B | |
+7.99% | 14.28B | |
+36.24% | 12.55B |
- Stock Market
- Equities
- PIRS Stock
- PIRS Stock